Actinogen Medical Ltd has released a press release.
ACW updated depression trial results and implications
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
In the deck
Earlier from Actinogen Medical
- ACW XanaCIDD phase 2a trial topline results
- ACW June 2024 quarterly activity report & Appendix 4C
- ACW XanaCIDD depression trial results expected early August
- Positive Xanamem biomarker trial published in Jnl Alz Dis
- ACW Oversubscribed $3.9 million entitlement offer completed
Later from Actinogen Medical
- ACW Appendix 4E and 2024 Annual Report
- ACW FY2024 results, advancing into late-stage trials
- Pause in Trading
- ACW $11.1m capital raising to accelerate Alzheimers trial
- $3.0 million share purchase plan closes 1.3x oversubscribed
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical